drugset
Drugs / Saredutant
last change Feb 2009 re-read 9 days ago

Saredutant

also known as SR48968C · Saredutant succinate · SR48968 · [<SUP>3</SUP>H]SAREDUTANT · CHEMBL308148

Small molecule targets TACR2 via inhibition

Developed for
depressive disorder · generalized anxiety disorder · major depressive disorder · anxiety
Investigated by
Sanofi

Trials 13

today NCT00629551 · Ph 3 NCT00531622 · Ph 3 NCT00429260 · Ph 3 NCT00415142 · Ph 3 NCT00417118 · Ph 3 NCT00390650 · Ph 3 NCT00390533 · Ph 3 NCT00336713 · Ph 3 NCT00250653 · Ph 3 NCT00250614 · Ph 3 NCT00250601 · Ph 3 NCT00256113 · Ph 3 NCT00250627 · Ph 3
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 313 trials
Phase 3 NCT00629551 Feb 2008 → Feb 2009 major depressive disorder Sanofi Completed No outcome recorded
Phase 3 NCT00531622 Sep 2007 → Jan 2009 major depressive disorder Sanofi Completed No outcome recorded
Phase 3 NCT00429260 Jan → Jun 2007 depressive disorder Sanofi Completed No outcome recorded
Phase 3 NCT00415142 Dec 2006 → Feb 2008 depressive disorder Sanofi Completed No outcome recorded
Phase 3 NCT00417118 Dec 2006 → Apr 2008 generalized anxiety disorder Sanofi Completed No outcome recorded
Phase 3 NCT00390650 Oct 2006 → Nov 2007 anxiety Sanofi Completed No outcome recorded
Phase 3 NCT00390533 Sep 2006 → Feb 2008 generalized anxiety disorder Sanofi Completed No outcome recorded
Phase 3 NCT00336713 May 2006 → Apr 2008 depressive disorder Sanofi Completed No outcome recorded
Phase 3 NCT00250653 May 2005 → Apr 2007 depressive disorder Sanofi Completed No outcome recorded
Phase 3 NCT00250614 Apr 2005 → Oct 2006 depressive disorder Sanofi Completed No outcome recorded

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 14 sources stand behind the page.

FieldValueCited text
Known as Saredutant ClinicalTrials.gov intervention name — accepted as the source's own label NCT00256113 ↗
12

NCT00415142 ↗

NCT00250601 ↗

NCT00250627 ↗

NCT00429260 ↗

NCT00250653 ↗

NCT00390533 ↗

NCT00336713 ↗

NCT00417118 ↗

NCT00250614 ↗

NCT00629551 ↗

Show 2 more sources
Known as [<SUP>3</SUP>H]SAREDUTANT ChEMBL registry synonym — accepted as the source's own label CHEMBL308148 ↗
Known as CHEMBL308148 ChEMBL registry synonym — accepted as the source's own label CHEMBL308148 ↗
Known as Saredutant succinate “Saredutant succinate (SR48968C)” NCT00250601 ↗
4

“Saredutant succinate (SR48968C)” NCT00256113 ↗

“Saredutant succinate (SR48968C)” NCT00250614 ↗

“Saredutant succinate (SR48968C)” NCT00250653 ↗

“Saredutant succinate (SR48968C)” NCT00250627 ↗
Known as SR48968 “Drug: saredutant (SR48968)” NCT00629551 ↗
2

“Drug: saredutant (SR48968)” NCT00415142 ↗

“saredutant (SR48968)” NCT00531622 ↗
Known as SR48968C “Saredutant succinate (SR48968C)” NCT00256113 ↗
5

“Saredutant succinate (SR48968C)” NCT00250627 ↗

“Saredutant succinate (SR48968C)” NCT00250601 ↗

“Saredutant succinate (SR48968C)” NCT00250614 ↗

“Saredutant succinate (SR48968C)” NCT00250653 ↗

“Saredutant (SR48968C)” NCT00336713 ↗
Action Inhibit “Neurokinin 2 receptor antagonist” CHEMBL308148 ↗
Modality Small molecule — CHEMBL308148 ↗
Route Oral “oral administration (capsules)” NCT00336713 ↗
Target TACR2 “Neurokinin 2 receptor antagonist” CHEMBL308148 ↗